Progyny saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 64 to 72.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Progyny can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
While now is not an ideal time to buy shares, see if the stock is able to form a chart pattern and break out.
Progyny saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 5% to 31%. Revenue rose from 2% to 11%.
The company holds the No. 4 rank among its peers in the Medical-Services industry group. Option Care Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
